OLMA
Olema Pharmaceuticals Inc

1,069
Loading...
Loading...
News
all
press releases
OLMA Stock Soars 47% in September So Far on Second PFE Deal
Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.
Zacks·21d ago
News Placeholder
More News
News Placeholder
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?
Zacks·5mo ago
News Placeholder
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent...
PR Newswire·10mo ago
News Placeholder
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 PR Newswire VANCOUVER...
PR Newswire·1y ago
News Placeholder
Olema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated by Analysts at The Goldman Sachs Group
The Goldman Sachs Group began coverage on shares of Olema Pharmaceuticals (NASDAQ:OLMA - Free Report) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm issued a...
Zolmax·2y ago
News Placeholder
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ( Olema or Olema Oncology , Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery...
Globe Newswire·2y ago
News Placeholder
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path...
SeekingAlpha·2y ago
News Placeholder
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of "Buy" by Analysts
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Get Free Report) has earned an average recommendation of Buy from the seven brokerages that are currently covering the stock...
Zolmax·2y ago
News Placeholder
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by EP Wealth Advisors LLC
EP Wealth Advisors LLC increased its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Free Report) by 831.1% in the third quarter, according to its most recent Form 13F filing...
Zolmax·2y ago
News Placeholder
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 11.9%
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Get Free Report)s share price shot up 11.9% during mid-day trading on Wednesday . The company traded as high as $13.59 and last traded at...
Ticker Report·2y ago

Latest OLMA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.